Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study

Wu, Tung-Han; Hu, Li-Yu; Lu, Tung‐Wu; Chen, Pan-Ming; Chen, Hon-Jhe; Shen, Cheng Che; Wen, Chia-Hsien

doi:10.1186/s10194-015-0548-y

Cited by 81 publications

(66 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, CRPS has an association with psychiatric disorders, including depression, and suicidal ideation 12. Trigeminal neuralgia also has a known association with depression, anxiety and sleep disorders 13. Furthermore, epilepsy is also associated with psychiatric comorbidities and risk of suicide 14.…”

Section: Discussionmentioning

confidence: 99%

Canadian neurosurgeons’ views on medical assistance in dying (MAID): a cross-sectional survey of Canadian Neurosurgical Society (CNSS) members

et al. 2019

View full text Add to dashboard Cite

BackgroundThe Supreme Court of Canada removed the prohibition on physicians assisting in patients dying on 6 February 2015. Bill C-14, legalising medical assistance in dying (MAID) in Canada, was subsequently passed by the House of Commons and the Senate on 17 June 2016. As this remains a divisive issue for physicians, the Canadian Neurosurgical Society (CNSS) has recently published a position statement on MAID.MethodsWe conducted a cross-sectional survey to understand the views and perceptions among CNSS members regarding MAID to inform its position statement on the issue. Data was collected from May to June 2016.ResultsOf the 300 active membes of the CNSS who recevied the survey, 89 respondents completed the survey, 71% of whom were attending neurosurgeons and 29% were neurosurgery residents. Most respondents,74.2%, supported the right of physicians to participate in MAID with 7.8% opposing. 37% had current patients in their practice fitting the criteria for MAID. 23.6% had been asked by patients to assist with MAID, but only 11% would consider personally providing it. 84% of neurosurgeons surveyed supported the physicians’ right to conscientious objection to MAID while 21% thought attending surgeons should be removed from the inquiry and decision-making process. 43.8% agreed that the requirment to refer a patient to a MAID service should be mandatory. Glioblastoma multiforme (65%), quadriplegia/quadriparesis secondary to spinal tumour/trauma (54%) and Parkinson’s disease (24%) were the most common suggested potential indications for MAID among the neurosurgical population.ConclusionsOur results demonstrate that most neurosurgeons in Canada are generally supportive of MAID in select patients. However, they also strongly support the physicians’ right to conscientious objection.

show abstract

Section: Discussionmentioning

confidence: 99%

Canadian neurosurgeons’ views on medical assistance in dying (MAID): a cross-sectional survey of Canadian Neurosurgical Society (CNSS) members

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Carbamazepine (CBZ) and oxcarbazepine (OXC) are the frequently used agents; on the other hand, nervousness, sleepiness, depression, gum diseases, concentration difficulties have been noted in patients (Besi et al 2015 ). In addition prolonged TN pain has been noted to increase anxiety disorders and cognitive impairments (Wu et al 2015 ). On the other hand late resistance to OXC and CBZ in cases of prolonged usage has been also noted (Di Stefano et al 2014 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of sphenopalatine ganglion blockade via intra oral route for the management of atypical trigeminal neuralgia

Çöven

Dayisoylu

2016

SpringerPlus

View full text Add to dashboard Cite

BackgroundThe sphenopalatine ganglion (SPG) may be involved in persistent idiopathic facial pain and unilateral headaches. The role of SPG blockade via intra oral route in the management of trigeminal neuralgia (TN) is worthy of study.MethodsIn this retrospective study, patient records included patients with atypical TN (type 2) that persisted in spite of conservative treatment for at least 2 years, and an average pain intensity from the craniofacial region visual analogue scale (VAS) before examination. In group I the patients received carmapazepin 800 mg a day for at least 2 years. In group II 3 ml of local anesthetic agent consisting 2 ml bupivacaine and 1 ml prilocain in addition to 1 ml fentanyl, 0.5 ml betametasone disodium phosphate and 0.5 ml opaque was injected by the intraoral route. In this group, injection procedures were performed under local anesthesia with fluoroscopic guidance. The Kruskal–Wallis and Mann–Whitney U tests with Bonferroni correction were used for intergroup analysis. Age and sex differences were evaluated with one-way ANOVA and Fisher’s exact tests, respectively.ResultsSignificant differences were found between pre-op and 3rd day VAS values and also pre-op and 1st month VAS values. No significant differences were found between pre-op and 6th month VAS values.ConclusionThe SPG blockade improves the quality of life of patients and a minimally-invasive procedure to management of TN, when compared to other methods.

show abstract

“…Epidemiological studies showed that approximately 4 to 28.9/100,000 persons worldwide experience TN [ 4 , 5 ]. Moreover, a recent large retrospective cohort study reported increased risk of depression and anxiety disorders in TN patients [ 6 ]. To date, the mechanisms underlying the pathogenesis of TN are still controversial; however, the microvascular compression is the most common hypothesis [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials

et al. 2016

View full text Add to dashboard Cite

BackgroundSeveral different interventions have been examined to alleviate pain and reduce frequency of trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible emerging choice of treatment for TN.MethodsWe conducted an electronic search in 10 databases/electronic search engines to access relevant publications. All articles in all languages reporting RCTs on the efficacy and safety of BTX-A in the treatment of TN were included for systematic review and meta-analysis.ResultsA total of four RCTs (n = 178) were identified for final meta-analysis. The overall effect favored BTX-A versus placebo in terms of proportion of responders (risk ratio RR = 2.87, 95 % confidence interval CI [1.76, 4.69], p <0.0001) with no significant detected heterogeneity (p = 0.31; I2 = 4 %). Paroxysms frequency per day was significantly lower for BTX-A group (mean difference MD = -29.79, 95 % CI [-38.50,–21.08], p <0.00001) with no significant heterogeneity (p = 0.21; I2 = 36 %).ConclusionDespite limited data, our results suggest that BTX-A may be an effective and safe treatment option for patients with TN. Further larger and well-designed RCTs are encouraged to translate these findings into better clinical outcome and better quality of life for TN patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s10194-016-0651-8) contains supplementary material, which is available to authorized users.

show abstract

Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study

Cited by 81 publications

References 60 publications

Canadian neurosurgeons’ views on medical assistance in dying (MAID): a cross-sectional survey of Canadian Neurosurgical Society (CNSS) members

Canadian neurosurgeons’ views on medical assistance in dying (MAID): a cross-sectional survey of Canadian Neurosurgical Society (CNSS) members

Evaluation of sphenopalatine ganglion blockade via intra oral route for the management of atypical trigeminal neuralgia

Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About